Genentech Biooncology
Genentech Biooncology
    • Home 

    • Research Education 

    • Research VEGF 

    • The role of VEGF across tumor types 

    • VEGF in bladder cancer 

    • VEGF and prognosis 

    • GLOSSARY
    • ON
    • OFF
  • Print
  • share
 
 
' The related resources bookmark allows you to jump directly to other pages on the site that contain information directly related to the topics you're currently exploring.
  • Home Page
  • What's New?
  • Tumor Types
  • Molecular Causes of Cancer
  • Biological Pathways
  • Therapeutic Targets
  • Pipeline Molecules
  • Research Education
    • Research ADCs
    • Research Apoptosis
    • Research B cell
    • Research BRAF
    • Research Cancer Immunotherapy
    • Research HDIs
    • Research HER Pathways
    • Research MET
    • Research VEGF
      • Why is the VEGF ligand essential throughout tumor development?
      • What are the strategies for inhibiting the VEGF pathway?
      • What are the effects of direct VEGF ligand inhibition?
      • Why is continued VEGF inhibition important?
      • Why do tumors progress?
      • The role of VEGF across tumor types
        • VEGF in lung cancer
        • VEGF in colorectal cancer
        • VEGF in renal cell carcinoma
        • VEGF in glioblastoma
        • VEGF in ovarian cancer
        • VEGF in bladder cancer
          • High VEGF expression
          • VEGF and prognosis
          • VEGF and progression
          • VEGF and progression in urothelial carcinoma
          • VEGF and MVD
          • MVD and progression
          • Summary
        • VEGF in gastric cancer
        • VEGF in multiple myeloma
        • VEGF in pancreatic cancer
      • Slide decks and videos
      • Glossary
  • Clinical Trials
  • Resources
  • Contact Us
Register for Updates Unsubscribe Share
Register for Updates Unsubscribe Share

Related Resources for this page:

  • Tumor Types
    • Colorectal Cancer
    • Glioblastoma
    • Lung Cancer
    • Ovarian Cancer
    • Pancreatic Cancer
    • Renal Cell Carcinoma
  • Molecular Causes of Cancer
    • Evading growth suppressors
    • Inducing angiogenesis
    • Activating invasion and metastasis
  • Biological Pathways
    • Angiogenic Signaling
    • Apoptosis
    • B-cell Surface Proteins
    • HER Signaling
    • MAPK Signaling
    • PI3K/Akt/mTOR Signaling
  • Therapeutic Targets
    • Bcl-2
    • HER1
    • HER2
    • HER3
    • HER4
    • VEGF
  • Future Directions
    • Antibody-Drug conjugates
      • HER Signaling
    • Glycoengineered Antibodies
      • HER Signaling
    • Non-Antibody Biologics
      • Apoptosis
    • Targeted Small Molecules
      • Apoptosis
      • MAPK Signaling
      • PI3K/Akt/mTOR Signaling
    • Traditional Monoclonal Antibodies
      • Angiogenic Signaling
      • B-cell Surface Proteins
      • HER Signaling

Video

Full VEGF & angiogenesis

View video now

Links

  • VEGF in NSCLC
  • VEGF in CRC
  • VEGF in RCC
  • VEGF in GBM
  • VEGF in ovarian cancer
  • VEGF in gastric cancer
  • VEGF in multiple myeloma
  • VEGF in pancreatic cancer
Share

VEGF and Prognosis in Bladder Cancer

Several studies have shown that vascular endothelial growth factor (VEGF) is a prognostic factor in superficial bladder cancer, as serum levels of VEGF are associated with tumor activity.1,2

For more specific information on activity related to VEGF expression, click on the links below.

In This Section

  • VEGF and progression in bladder cancer
  • VEGF and progression in urothelial carcinoma
  • VEGF and MVD
  • MVD and progression
References:
1.
Crew JP, O'Brien T, Bradburn M, et al. Cancer Res. 1997;57:5281-5285. PMID: 9393750
2.
Bernardini S, Fauconnet S, Chabannes E, et al. J Urol. 2001;166:1275-1279. PMID: 11547057
 
  • SITEMAP
  • /
  • PRIVACY POLICY
  • /
  • TERMS & CONDITIONS
  • /
  • CONTACT US
  • /
  • © 2013 Genentech USA, Inc. All rights reserved.
  • /
  • BIO0000907901
Next section: VEGF and progression »

© 2011 Genentech USA, Inc. All rights reserved